As mandated by NCI SPORE Guidelines, the University of Texas Special Program of Research Excellence (SPORE) has a Career Enhancement Program (CEP). The SPORE CEP is funded by a combination of NCI SPORE grant support ($50,000 direct costs) and Institutional support from UTSW and MDACC ($150,000 direct costs) for a total budget of $200,000. With average awards of $25,000, this permits ~8 CEP Awards per year.
The Specific Aims of the CEP are: 1. Maintain lung cancer translational research excellence at UTSW and MDACC by recruitment of highly innovative and talented clinical, applied, and basic scientists at all levels. 2. Promote the career enhancement of highly qualified clinical oncologists, applied, and basic scientists, both within UTSW and MDACC and outside of these institutions, with the ability to rapidly translate their findings into clinically applicable utility for lung cancer. 3. Attract candidates with prior experience in cancer at other disease sites who want to acquire expertise in lung cancer translational research. 4. Promote transition of CEP awardees from mentored investigators to successful independent lung cancer translational research scientists including helping them prepare other peer-reviewed funding applications. The overall CEP goal(s) is to fund UTSW, MDACC young faculty with MD or PhD degrees (senior post doctoral fellow transitioning to faculty, Instructor, Assistant and Associate Professor level) who want to pursue a career in lung cancer research and who have prepared an application with high potential for significant impact on lung cancer pathogenesis, diagnosis, prevention, prognosis, or therapy. As part of this program, awardees will have access to Lung Cancer SPORE Core resources (such as preclinical models, Molecular Pathology, Data Sciences), and access to mentorship by experienced lung cancer investigators and patient advocates. CEP Awardees will bring new and innovative ideas and approaches to lung cancer translational research; in turn, they will receive training in new approaches, concepts, technologies, data gathering and analyses for understanding lung cancer biology, pathogenesis, diagnosis and therapy. The CEP is run by the SPORE MPIs from UTSW and MDACC (Minna, Gerber, Roth, Heymach). Applications are scored by the SPORE External Advisory Board (EAB) based on the applicant?s ability and the project?s significance, innovation, approach, research environment, and potential impact. Special efforts are made to recruit women and minority applicants. Over the 20-year history of this SPORE, the CEP has been very successful, leading to a large number of awardees whose careers have been enhanced by the awards, including publications, generation of preliminary information for obtaining other grants, academic promotion, and progression to playing major roles in SPORE Projects and Cores.

Public Health Relevance

Career Enhancement Program (CEP) Project Narrative The Lung Cancer SPORE Career Enhancement Program (CEP) provides pilot project funding for lung cancer projects, prepared by early career faculty investigators with the potential for clinical translation with significant impact on the diagnosis, prevention, or treatment of lung cancer. With this funding comes access to SPORE Core Pathology and Data Sciences Resources and mentorship by experienced lung cancer investigators and patient advocates. These pilot projects should lead to publications, applications for other grant funding and, as appropriate, clinical trial development, and advancement as part of the overall SPORE Program..

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-21A1
Application #
10023870
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Shidan; Chen, Alyssa; Yang, Lin et al. (2018) Comprehensive analysis of lung cancer pathology images to discover tumor shape and boundary features that predict survival outcome. Sci Rep 8:10393
Gomez, Daniel Richard; Byers, Lauren Averett; Nilsson, Monique et al. (2018) Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9:14268-14284
Parra, Edwin R; Villalobos, Pamela; Mino, Barbara et al. (2018) Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 26:83-93
Yamauchi, Mitsuo; Barker, Thomas H; Gibbons, Don L et al. (2018) The fibrotic tumor stroma. J Clin Invest 128:16-25
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113
Yi, Faliu; Yang, Lin; Wang, Shidan et al. (2018) Microvessel prediction in H&E Stained Pathology Images using fully convolutional neural networks. BMC Bioinformatics 19:64
Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48

Showing the most recent 10 out of 1059 publications